Functional imaging of the heart and brain

Lead Research Organisation: University of Oxford
Department Name: Clinical Neurosciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Publications


10 25 50
 
Description Engagement with MHRA for establishing an expert or "superuser" group to help the UK community best respond to MHRA guidelines for PET
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Public consultation roll out of participant involvement in research- MRC/WT sponsorted
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Changes in perception of clinical trials
 
Title Evaluation of IL2 as a fluorinated PET tracer 
Description IL2 can be a used as a molecular probe for T-cells in humans. The work refined and evaluated a method for preparation that had been described by European collaborators. Unfortunately, we proved it to degrade the molecule and hence are developing new approaches. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact The work has informed R and D in GSK, which had been intending to apply the F-IL2 tracer 
 
Title Genotypic modelling of TSPO PET 
Description Defined how to use common polymorphism to better model an inflammatory marker 
Type Of Material Technology assay or reagent 
Year Produced 2011 
Provided To Others? Yes  
Impact Genotyping now routinely incorporated into research practice 
 
Title Implementation of radiotracers for research use 
Description A number of radiotracers were newly implemented in the UK Imanova centre including rolipram, PBR28, PBR111 and additional work was done to make PE2I avaliable. 
Type Of Material Technology assay or reagent 
Year Produced 2011 
Provided To Others? Yes  
Impact GSK and Imperial college based resarchers are starting or preparing to start clinical studies. 
 
Title Ligand development 
Description Lead GSK imaging centre for validation of novel H3, 5HT2, PHNO use and D3 radioligands 
Type Of Material Technology assay or reagent 
Year Produced 2009 
Provided To Others? Yes  
Impact Use of PHNO in dopamine release experiments 
 
Description Cambridge 
Organisation Medical Research Council (MRC)
Department MRC Cognition and Brain Sciences Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Imgaging environment, expertise
Collaborator Contribution Staffing, collaborative development of reserach protocols, execution and analysis
Impact Papers, support for case for imaging investment by CBU
 
Description European FP7 Marie Curie Collaboration 
Organisation Research Centre Juelich GmbH
Department Institute of Neuroscience and Medicine
Country Germany, Federal Republic of 
Sector Public 
PI Contribution Constitute phFMRI component of multisite Neurophysics Collaboration
Collaborator Contribution Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints
Impact Multi-disciplinary PhDs in progress
Start Year 2009
 
Description European FP7 Marie Curie Collaboration 
Organisation University of Maastricht (UM)
Department Maastricht School for Mental Health and Neuroscience (MHeNS)
Country Netherlands, Kingdom of the 
Sector Academic/University 
PI Contribution Constitute phFMRI component of multisite Neurophysics Collaboration
Collaborator Contribution Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints
Impact Multi-disciplinary PhDs in progress
Start Year 2009
 
Description European FP7 Marie Curie Collaboration 
Organisation University of Oxford
Department Oxford Centre for Functional MRI of the Brain FMRIB
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Constitute phFMRI component of multisite Neurophysics Collaboration
Collaborator Contribution Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints
Impact Multi-disciplinary PhDs in progress
Start Year 2009
 
Description European FP7 Marie Curie Collaboration 
Organisation University of Warwick
Department Department of Statistics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Constitute phFMRI component of multisite Neurophysics Collaboration
Collaborator Contribution Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints
Impact Multi-disciplinary PhDs in progress
Start Year 2009
 
Description FMRIB Centre Oxford 
Organisation John Radcliffe Hospital
Department Centre for Functional MRI of the Brain (fMRI)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Collaborative supervision of fellows and research
Collaborator Contribution Collaborative research, support for fellows and students, research environment
Impact Papers since 2006 with FMRIB coauthors
 
Description MNI 
Organisation McGill University
Department Montreal Neurological Institute
Country Canada 
Sector Academic/University 
PI Contribution Staff, patient material, scanning time
Collaborator Contribution Patient recruitment, scanning time, collaborative experimental design and implementation
Impact Multiple papers, commercial support to GSK, gudielines for clinical use of MRI
 
Description Siena 
Organisation University of Siena
Department Neurology Siena
Country Italy, Italian Republic 
Sector Academic/University 
PI Contribution Collaborative research design, execution and analysis
Collaborator Contribution Staff, patient material, scanning time
Impact Multiple publications and guidelines for use of clinical MRI
 
Description Training collaboration 
Organisation GE Healthcare
Department Nuclear Medicine
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.
Collaborator Contribution Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment
Impact None
Start Year 2010
 
Description Training collaboration 
Organisation Imanova
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.
Collaborator Contribution Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment
Impact None
Start Year 2010
 
Description Training collaboration 
Organisation University of Manchester
Department Wolfson Molecular Imaging Centre (WMIC)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.
Collaborator Contribution Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment
Impact None
Start Year 2010
 
Description Training collaboration 
Organisation University of Newcastle
Department Radiochemistry Department of Chemisry
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue.
Collaborator Contribution Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment
Impact None
Start Year 2010
 
Description UK Biobank 
Organisation UK Biobank
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Expert input as member of steering committee and chair of working group
Collaborator Contribution Organisational structure and expertise
Impact Open access to database 2013 Publications describing Imaging Enhancment Successful funding for imaging enhancement and set up of new centre
Start Year 2008
 
Title GlaxoSmithKline Early Development 
Description Over last 5 years, research and group have contributed to development of more than 18 different molecules in early development (see letter from Dr. Phil Murphy in 2013 REF submission). Here these contributions all have been "lumped" into a single entry 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2013
Development Status Actively seeking support
Impact reducing costs for commercial development, increased competitiveness of UK environment 
 
Company Name Imanova, Ltd. 
Description Imanova is a molecular and functional imaging service company. This funding programme further demonstrated the value of public-private partnerships in this area to GSK, who led in formation of the new company. The programme continues to support Imanova and is not providing the latter with a model for training. 
Year Established 2011 
Impact Has established proof of principle for training in radiochemistry in the context of this kind of company
Website http://www.imanova.co.uk/
 
Description Bard 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Wrote popular book to highlight brain research- "Bard on the Brain". Follow up lectures. Led to creation of Oxford Centre for the Creative Brain

Multiple public presentation requests inUK, Europe and US
Year(s) Of Engagement Activity 2006,2009,2015
 
Description Head of Div coordination of open day for patients and charities 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Divisional open day attended by about 100 patients, carers, and charity

Follow up article in Daily Telegraph on line
Year(s) Of Engagement Activity 2012